Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with K D s of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness.
性状
Liquid
IC50 & Target[1][2]
ACVR2B 1.7 pM (Kd) ACVR2A 434 pM (Kd)
体外研究(In Vitro)
BYM338 (1 pM-1 μM; 24 h) 抑制 HEK293 细胞中 Myostatin 和 Activin A- 诱导的 Smad2/3 依赖性荧光素酶反应,IC50 值分别为 154 和 343。BYM338 (4 days) 可防止外源添加 Myostatin 或 Activin A 诱导的分化和融合抑制。 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
BYM338 (6-20 mg/kg; 皮下注射,每周一次,持续 4 周) 促进所有检查肌肉的体重增加和骨骼肌肥大,包括慢速、快速和混合肌肉。
BYM338 (5-20 mg/kg;皮下注射,每周一次,持续 14 天) 可防止糖皮质激素诱导的小鼠肌肉萎缩[2]。 has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Heymsfield SB, et, al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021 Jan 4;4(1):e2033457. [2]. Lach-Trifilieff E, et, al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014 Feb;34(4):606-18.